These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63. Ultrasonographic screening for trisomy 21. Bernstein IM Am J Obstet Gynecol; 1992 May; 166(5):1591. PubMed ID: 1534447 [No Abstract] [Full Text] [Related]
64. [The frequency of amniocentesis in pregnant women 35 years or over in the County of Storstrøm. A retrospective study of all pregnant women 35 years or over from 1.10.1978 to 1.10.1980]. Bo JO; Pedersen MG Ugeskr Laeger; 1982 Jul; 144(30):2218-9. PubMed ID: 7147421 [No Abstract] [Full Text] [Related]
65. Sonographic demonstration of uterine contraction during amniocentesis. Finberg HJ; Frigoletto FD Am J Obstet Gynecol; 1981 Mar; 139(6):740-2. PubMed ID: 7211981 [No Abstract] [Full Text] [Related]
67. Termination of pregnancy after positive result for fetal anomaly due to second trimester ultrasonography screening: an appraisal. Wiwanitkit V J Turk Ger Gynecol Assoc; 2009; 10(3):186. PubMed ID: 24591868 [No Abstract] [Full Text] [Related]
68. Prenatal screening for Down's syndrome with use of maternal serum markers. Haddow JE; Palomaki GE; Knight GJ; Williams J; Pulkkinen A; Canick JA; Saller DN; Bowers GB N Engl J Med; 1992 Aug; 327(9):588-93. PubMed ID: 1379344 [TBL] [Abstract][Full Text] [Related]
69. Effectiveness of combining maternal serum alpha-fetoprotein and hCG in a second-trimester screening program for Down syndrome. Mooney RA; Peterson CJ; French CA; Saller DN; Arvan DA Obstet Gynecol; 1994 Aug; 84(2):298-303. PubMed ID: 7518896 [TBL] [Abstract][Full Text] [Related]
70. The use of second-trimester genetic sonogram in guiding clinical management of patients at increased risk for fetal trisomy 21. Vintzileos AM; Campbell WA; Rodis JF; Guzman ER; Smulian JC; Knuppel RA Obstet Gynecol; 1996 Jun; 87(6):948-52. PubMed ID: 8649704 [TBL] [Abstract][Full Text] [Related]
71. Prenatal screening using maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol: two-year experience in a health maintenance organization. McDuffie RS; Haverkamp AD; Stark CF; Haverkamp C; Barth CK J Matern Fetal Med; 1996; 5(2):70-3. PubMed ID: 8796771 [TBL] [Abstract][Full Text] [Related]
72. [Evaluation of the association of a serum marker and second trimester ultrasonography for the screening of trisomy 21 in women of less than 38 years. Prospective study of 5,163 patients]. Lefebvre G; Vauthier-Brouzes D; Choukroun JB; Sebagh E; Bernard M; Brochet C; Lesourd S; Darbois Y J Gynecol Obstet Biol Reprod (Paris); 1998 Oct; 27(6):599-604. PubMed ID: 9854223 [TBL] [Abstract][Full Text] [Related]
73. Down syndrome: prenatal risk assessment and diagnosis. Newberger DS Am Fam Physician; 2000 Aug; 62(4):825-32, 837-8. PubMed ID: 10969860 [TBL] [Abstract][Full Text] [Related]
74. Is genetic ultrasound cost-effective? DeVore GR Semin Perinatol; 2003 Apr; 27(2):173-82. PubMed ID: 12769203 [TBL] [Abstract][Full Text] [Related]